Cargando…

WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target

BACKGROUND: Overexpression of Wilms’ tumor-1 (WT1) transcription factor facilitates proliferation in acute myeloid leukemia (AML). However, whether WT1 is enriched in the leukemia-initiating cells (LICs) and leukemia stem cells (LSCs) and facilitates the self-renewal of LSCs remains poorly understoo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Bin, Jin, Xianghong, Jin, Weiwei, Huang, Xingzhou, Wu, Yanfei, Li, Haiying, Zhu, Weijian, Qin, Xiaoyi, Ye, Haige, Gao, Shenmeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313134/
https://www.ncbi.nlm.nih.gov/pubmed/32580769
http://dx.doi.org/10.1186/s12967-020-02384-y
_version_ 1783549888686981120
author Zhou, Bin
Jin, Xianghong
Jin, Weiwei
Huang, Xingzhou
Wu, Yanfei
Li, Haiying
Zhu, Weijian
Qin, Xiaoyi
Ye, Haige
Gao, Shenmeng
author_facet Zhou, Bin
Jin, Xianghong
Jin, Weiwei
Huang, Xingzhou
Wu, Yanfei
Li, Haiying
Zhu, Weijian
Qin, Xiaoyi
Ye, Haige
Gao, Shenmeng
author_sort Zhou, Bin
collection PubMed
description BACKGROUND: Overexpression of Wilms’ tumor-1 (WT1) transcription factor facilitates proliferation in acute myeloid leukemia (AML). However, whether WT1 is enriched in the leukemia-initiating cells (LICs) and leukemia stem cells (LSCs) and facilitates the self-renewal of LSCs remains poorly understood. METHODS: MLL-AF9-induced murine leukemia model was used to evaluate the effect of knockdown of wt1 on the self-renewal ability of LSC. RNA sequencing was performed on WT1-overexpressing cells to select WT1 targets. Apoptosis and colony formation assays were used to assess the anti-leukemic potential of a deubiquitinase inhibitor WP1130. Furthermore, NOD/SCID-IL2Rγ (NSG) AML xenotransplantation and MLL-AF9-induced murine leukemia models were used to evaluate the anti-leukemogenic potential of WP1130 in vivo. RESULTS: We found that wt1 is highly expressed in LICs and LSCs and facilitates the maintenance of leukemia in a murine MLL-AF9-induced model of AML. WT1 enhanced the self-renewal of LSC by increasing the expression of BCL2L2, a member of B cell lymphoma 2 (BCL2) family, by direct binding to its promoter region. Loss of WT1 impaired self-renewal ability in LSC and delayed the progression of leukemia. WP1130 was found to modify the WT1-BCL2L2 axis, and WP1130-induced anti-leukemic activity was mediated by ubiquitin proteasome-mediated destruction of WT1 protein. WP1130 induced apoptosis and decreased colony formation abilities of leukemia cells and prolonged the overall survival in the THP1-based xenograft NSG mouse model. WP1130 also decreased the frequency of LSC and prolonged the overall survival in MLL-AF9-induced murine leukemia model. Mechanistically, WP1130 induced the degradation of WT1 by positively affecting the ubiquitination of WT1 protein. CONCLUSIONS: Our results indicate that WT1 is required for the development of AML. WP1130 exhibits anti-leukemic activity by inhibiting the WT1-BCL2L2 axis, which may represent a new acute myeloid leukemia therapy target.
format Online
Article
Text
id pubmed-7313134
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73131342020-06-24 WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target Zhou, Bin Jin, Xianghong Jin, Weiwei Huang, Xingzhou Wu, Yanfei Li, Haiying Zhu, Weijian Qin, Xiaoyi Ye, Haige Gao, Shenmeng J Transl Med Research BACKGROUND: Overexpression of Wilms’ tumor-1 (WT1) transcription factor facilitates proliferation in acute myeloid leukemia (AML). However, whether WT1 is enriched in the leukemia-initiating cells (LICs) and leukemia stem cells (LSCs) and facilitates the self-renewal of LSCs remains poorly understood. METHODS: MLL-AF9-induced murine leukemia model was used to evaluate the effect of knockdown of wt1 on the self-renewal ability of LSC. RNA sequencing was performed on WT1-overexpressing cells to select WT1 targets. Apoptosis and colony formation assays were used to assess the anti-leukemic potential of a deubiquitinase inhibitor WP1130. Furthermore, NOD/SCID-IL2Rγ (NSG) AML xenotransplantation and MLL-AF9-induced murine leukemia models were used to evaluate the anti-leukemogenic potential of WP1130 in vivo. RESULTS: We found that wt1 is highly expressed in LICs and LSCs and facilitates the maintenance of leukemia in a murine MLL-AF9-induced model of AML. WT1 enhanced the self-renewal of LSC by increasing the expression of BCL2L2, a member of B cell lymphoma 2 (BCL2) family, by direct binding to its promoter region. Loss of WT1 impaired self-renewal ability in LSC and delayed the progression of leukemia. WP1130 was found to modify the WT1-BCL2L2 axis, and WP1130-induced anti-leukemic activity was mediated by ubiquitin proteasome-mediated destruction of WT1 protein. WP1130 induced apoptosis and decreased colony formation abilities of leukemia cells and prolonged the overall survival in the THP1-based xenograft NSG mouse model. WP1130 also decreased the frequency of LSC and prolonged the overall survival in MLL-AF9-induced murine leukemia model. Mechanistically, WP1130 induced the degradation of WT1 by positively affecting the ubiquitination of WT1 protein. CONCLUSIONS: Our results indicate that WT1 is required for the development of AML. WP1130 exhibits anti-leukemic activity by inhibiting the WT1-BCL2L2 axis, which may represent a new acute myeloid leukemia therapy target. BioMed Central 2020-06-24 /pmc/articles/PMC7313134/ /pubmed/32580769 http://dx.doi.org/10.1186/s12967-020-02384-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhou, Bin
Jin, Xianghong
Jin, Weiwei
Huang, Xingzhou
Wu, Yanfei
Li, Haiying
Zhu, Weijian
Qin, Xiaoyi
Ye, Haige
Gao, Shenmeng
WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target
title WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target
title_full WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target
title_fullStr WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target
title_full_unstemmed WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target
title_short WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target
title_sort wt1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of bcl2l2: wt1-bcl2l2 axis as a new acute myeloid leukemia therapy target
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313134/
https://www.ncbi.nlm.nih.gov/pubmed/32580769
http://dx.doi.org/10.1186/s12967-020-02384-y
work_keys_str_mv AT zhoubin wt1facilitatestheselfrenewalofleukemiainitiatingcellsthroughtheupregulationofbcl2l2wt1bcl2l2axisasanewacutemyeloidleukemiatherapytarget
AT jinxianghong wt1facilitatestheselfrenewalofleukemiainitiatingcellsthroughtheupregulationofbcl2l2wt1bcl2l2axisasanewacutemyeloidleukemiatherapytarget
AT jinweiwei wt1facilitatestheselfrenewalofleukemiainitiatingcellsthroughtheupregulationofbcl2l2wt1bcl2l2axisasanewacutemyeloidleukemiatherapytarget
AT huangxingzhou wt1facilitatestheselfrenewalofleukemiainitiatingcellsthroughtheupregulationofbcl2l2wt1bcl2l2axisasanewacutemyeloidleukemiatherapytarget
AT wuyanfei wt1facilitatestheselfrenewalofleukemiainitiatingcellsthroughtheupregulationofbcl2l2wt1bcl2l2axisasanewacutemyeloidleukemiatherapytarget
AT lihaiying wt1facilitatestheselfrenewalofleukemiainitiatingcellsthroughtheupregulationofbcl2l2wt1bcl2l2axisasanewacutemyeloidleukemiatherapytarget
AT zhuweijian wt1facilitatestheselfrenewalofleukemiainitiatingcellsthroughtheupregulationofbcl2l2wt1bcl2l2axisasanewacutemyeloidleukemiatherapytarget
AT qinxiaoyi wt1facilitatestheselfrenewalofleukemiainitiatingcellsthroughtheupregulationofbcl2l2wt1bcl2l2axisasanewacutemyeloidleukemiatherapytarget
AT yehaige wt1facilitatestheselfrenewalofleukemiainitiatingcellsthroughtheupregulationofbcl2l2wt1bcl2l2axisasanewacutemyeloidleukemiatherapytarget
AT gaoshenmeng wt1facilitatestheselfrenewalofleukemiainitiatingcellsthroughtheupregulationofbcl2l2wt1bcl2l2axisasanewacutemyeloidleukemiatherapytarget